AlphaCentric Advisors’s Cytokinetics CYTK Stock Holding History

AlphaCentric Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$485K	Buy	5,697 +81	+1%	+$5.82K	0.41%	88
2026 Q1	$370K	Buy	5,616 +305	+6%	+$19.4K	0.37%	94
2025 Q4	$337K	Buy	+5,311	New	+$330K	0.34%	98
2024 Q4	–	Sell	-12,500	Closed	-$660K	–	225
2024 Q3	$660K	Buy	+12,500	New	+$697K	0.49%	60
2021 Q2	–	Sell	-12,500	Closed	-$291K	–	220
2021 Q1	$291K	Hold	12,500	–	–	0.1%	76
2020 Q4	$260K	Buy	+12,500	New	+$228K	0.11%	50

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCentric Advisors's CYTK Position: Q2 2026 in Review

AlphaCentric Advisors increased its Cytokinetics (CYTK) stake by 1.4% in Q2 2026, buying an estimated $5.82K and bringing the position to 5,697 shares worth $485K. The position accounts for 0.41% of the portfolio, ranked #88.

AlphaCentric Advisors first reported a position in CYTK in Q4 2020 and has held it in 6 quarters since. The position peaked at $660K in Q3 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

AlphaCentric Advisors held 5,697 shares of Cytokinetics worth $485K as of Q2 2026.
AlphaCentric Advisors bought 81 Cytokinetics shares in Q2 2026, an estimated $5.82K.
Cytokinetics made up 0.41% of AlphaCentric Advisors's portfolio in Q2 2026, its #88 holding.
AlphaCentric Advisors first reported a position in Cytokinetics in Q4 2020 and has held it in 6 quarters since.
AlphaCentric Advisors's Cytokinetics position peaked at $660K in Q3 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.